Public Employees Retirement Association of Colorado bought a new stake in shares of Catalent Inc (NYSE:CTLT) in the fourth quarter, HoldingsChannel reports. The fund bought 16,119 shares of the company’s stock, valued at approximately $662,000.
Several other institutional investors have also recently made changes to their positions in CTLT. Stifel Financial Corp increased its holdings in shares of Catalent by 0.9% in the second quarter. Stifel Financial Corp now owns 10,694 shares of the company’s stock valued at $377,000 after purchasing an additional 96 shares during the last quarter. Royal Bank of Canada increased its holdings in shares of Catalent by 46.7% in the second quarter. Royal Bank of Canada now owns 35,029 shares of the company’s stock valued at $1,230,000 after purchasing an additional 11,151 shares during the last quarter. The Manufacturers Life Insurance Company increased its holdings in shares of Catalent by 8.6% in the second quarter. The Manufacturers Life Insurance Company now owns 276,283 shares of the company’s stock valued at $9,697,000 after purchasing an additional 21,956 shares during the last quarter. California State Teachers Retirement System increased its holdings in shares of Catalent by 13.6% in the second quarter. California State Teachers Retirement System now owns 222,934 shares of the company’s stock valued at $7,825,000 after purchasing an additional 26,707 shares during the last quarter. Finally, Nomura Holdings Inc. acquired a new stake in shares of Catalent in the second quarter valued at approximately $220,000. 99.82% of the stock is owned by institutional investors and hedge funds.
CTLT has been the subject of several recent research reports. Zacks Investment Research raised Catalent from a “hold” rating to a “buy” rating and set a $48.00 price target for the company in a report on Wednesday, January 17th. Goldman Sachs Group initiated coverage on Catalent in a report on Wednesday, January 24th. They issued a “buy” rating and a $50.00 price target for the company. Royal Bank of Canada set a $48.00 price target on Catalent and gave the company a “buy” rating in a report on Monday, February 5th. Bank of America increased their price target on Catalent from $47.00 to $49.00 and gave the company a “buy” rating in a report on Tuesday, February 6th. Finally, ValuEngine raised Catalent from a “hold” rating to a “buy” rating in a report on Wednesday, February 7th. Six analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Catalent presently has an average rating of “Buy” and a consensus price target of $45.60.
In other Catalent news, Director Uwe Roehrhoff acquired 7,500 shares of the stock in a transaction that occurred on Tuesday, November 21st. The stock was bought at an average cost of $39.22 per share, for a total transaction of $294,150.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider John R. Chiminski sold 181,458 shares of the stock in a transaction that occurred on Tuesday, December 12th. The stock was sold at an average price of $39.62, for a total value of $7,189,365.96. The disclosure for this sale can be found here. Corporate insiders own 1.70% of the company’s stock.
Catalent Inc (NYSE CTLT) opened at $43.37 on Monday. The firm has a market capitalization of $5,782.03, a P/E ratio of 76.09, a P/E/G ratio of 2.49 and a beta of 1.47. Catalent Inc has a 52-week low of $27.48 and a 52-week high of $47.87. The company has a debt-to-equity ratio of 2.66, a current ratio of 2.22 and a quick ratio of 1.78.
Catalent (NYSE:CTLT) last issued its quarterly earnings data on Monday, February 5th. The company reported $0.41 earnings per share for the quarter, topping the consensus estimate of $0.31 by $0.10. The company had revenue of $606.30 million during the quarter, compared to analyst estimates of $565.05 million. Catalent had a return on equity of 23.85% and a net margin of 3.03%. The firm’s revenue for the quarter was up 25.3% compared to the same quarter last year. During the same period in the prior year, the business posted $0.27 earnings per share. analysts anticipate that Catalent Inc will post 1.53 EPS for the current fiscal year.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Want to see what other hedge funds are holding CTLT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalent Inc (NYSE:CTLT).
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.